AstraZeneca has penned a pact to develop bicyclic peptides with Bicycle Therapeutics.

CAR-T biotech Bluebird Bio has released topline data for its experimental med bb2121 in heavily pretreated multiple myeloma in a small, positive study that has…

Longwood Fund and Domain Associates have led a $19.15 million funding round for newco Axial Biotherapeutics with the aim of creating new treatments for an…

A few weeks back, and in fact the day before the U.S. election, RNAi biotech Arrowhead quietly posted some miserable news that its hep B candidate, ARC-520,…

Pfizer and Merck KGaA took a step closer to becoming the fourth to market in the new checkpoint inhibitor space as they announce that the FDA has accepted for…

Boehringer teams up with a Chinese research group to tackle disabling hearing loss, which affects millions of people worldwide.

AstraZeneca’s biologics arm MedImmune and synthetic biology co Abpro have joined forces on a new Ang2-VEGF research collab that will come together under a new…

Amicus saw its shares down by 26% after news that its Fabry disease candidate migalastat did not meet the FDA’s requirements for a speedy review, and the…

R&D